Belgium offers a skilled labourforce, with a high educational level, who are mostly multilingual. In a similar way to other countries of smaller size, its people…
In Conversation
We have no doubts about committing our resources and funds to Belgium ... as we are confident of the environment of broad alignment between authorities, HCPs,…
Ultimately, the goal is to transition from the current acute care business model, where patients primarily seek care in hospitals when they are already in need,…
We hope to see more collaboration at the European level which would mitigate the national differences across Europe on patient access to treatments
With COVID’s high demands and the drive for Co2 reductions, the maritime sector is growing in importance within the healthcare supply chain
The complexities of conditions like cancer demand a revolutionary solution. That is where CAR-T cell therapy could be a potential game-changer
Frontier markets, particularly in Africa, present great opportunities for setting up facilities for vaccine manufacturing and indeed entire biotech ecosystems
Belgian healthcare is under huge pressure to balance the costs associated with new innovations, but continual price cuts for generics are threatening the system’s sustainability and…
By investing so much in the Belgian ecosystem, we can be an important player on several fronts, leveraging the voice of the innovative industry
The only critical success factor in moving forward and getting innovative products reimbursed is for pharmaceutical companies to be seen as a real partner; a real…
Patients are the true experts as the only actors that know what living with a condition is like and the impact of a treatment on how…
In Belgium we are generally good at treating conditions but not so good at preventing them, and this is also the case with diabetes
